Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 121 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Streptococcus Pneumoniae Infection Clear all

Conditions: Pneumococcal Disease
Interventions: Low dose multivalent pneumococcal conjugate vaccine formulation A, Low dose multivalent pneumococcal conjugate vaccine formulation B, Low dose of multivalent pneumococcal conjugate vaccine control, Standard dose multivalent pneumococcal conjugate vaccine control; Other · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 64 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Hialeah, Florida • Hollywood, Florida • Columbia, Maryland + 4 more

Conditions: Leukemia
Interventions: Sargramostim (GM-CSF), Pneumococcal Vaccine; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Invasive Pneumococcal Disease
Interventions: No intervention; Other
Lead sponsor: Pfizer; Industry
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Oakland, California

Conditions: Pneumococcal Disease
Interventions: PG4, 20-valent pneumococcal conjugate vaccine (20vPnC); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 42 Days to 98 Days
Enrollment: 2,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 26
States / cities: Estero, Florida • Fort Lauderdale, Florida • Fort Myers, Florida + 19 more

Conditions: Pneumococcal Infections
Interventions: V114, QIV, Matching Placebo for V114; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 45
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 39 more

Conditions: Pneumococcal Infection
Interventions: PPV23; Biological
Lead sponsor: University of Toledo Health Science Campus; Other
Eligibility: 19 Years to 65 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Pneumococcal Infections
Interventions: V114, Prevnar 13™, PNEUMOVAX™23; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 3 Years and older
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 13
States / cities: Palo Alto, California • Aurora, Colorado • Gainesville, Florida + 10 more

Conditions: Diphtheria, Tetanus, Haemophilus Infection, Pertussis, Polio
Interventions: Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 42 Days to 89 Days
Enrollment: 1,167 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 23
States / cities: Montgomery, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 19 more

Conditions: Pneumonia
Interventions: Salmonella Typhi-vectored pneumonia vaccine; Biological
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Pneumococcal Disease
Interventions: Experimental 20-valent pneumococcal conjugate vaccine (20vPnC), Saline, Influenza vaccine; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years and older
Enrollment: 1,796 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 63
States / cities: Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 53 more

Conditions: Pneumococcal Infections
Interventions: Pneumovax 23; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Heart Transplant Infection Prevention
Interventions: PCV15; Biological
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Pneumococcal Disease
Interventions: PG4, 20-valent pneumococcal conjugate vaccine (20vPnC); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 15 Months to 17 Years
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 62
States / cities: Birmingham, Alabama • Guntersville, Alabama • Fair Oaks, California + 37 more

Conditions: Pneumococcal Infections
Interventions: V114 Lot 1, V114 Lot 2, Prevnar 13™; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 6 Weeks to 12 Weeks
Enrollment: 1,051 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 30
States / cities: Birmingham, Alabama • Dothan, Alabama • Jonesboro, Arkansas + 27 more

Conditions: Pneumonia, Pneumococcal Infections, Infections, Streptococcus Pneumoniae
Interventions: Prevnar, Pneumovax; Biological
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pneumococcal Disease
Interventions: 13vPnC, PPSV23, 20vPnC; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years and older
Enrollment: 875 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 34
States / cities: Mobile, Alabama • Chandler, Arizona • Peoria, Arizona + 26 more

Conditions: Pneumococcal Disease
Interventions: PG4, 20-valent pneumococcal conjugate vaccine (20vPnC); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 12 Months to 15 Months
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 35
States / cities: Washington D.C., District of Columbia • Miami, Florida • Chamblee, Georgia + 18 more

Conditions: Pneumococcal Disease
Interventions: PG4, 20-valent pneumococcal conjugate vaccine (20vPnC); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 42 Days to 211 Days
Enrollment: 3,230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 111
States / cities: Bessemer, Alabama • Birmingham, Alabama • Fayetteville, Arkansas + 74 more

Conditions: HIV, Pneumococcal Infections, Pneumococcal Vaccines
Interventions: PCV-13, PPSV-23; Biological
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2021
U.S. locations: 3
States / cities: Aurora, Colorado • Denver, Colorado

Conditions: Pneumococcal Infection
Interventions: V116, PCV20; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 2,663 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 60
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 52 more

Conditions: Otitis Media
Interventions: Tympanocentesis, Nose/throat swab, Observational; Procedure · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 6 Months to 30 Months
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 7
States / cities: Penfield, New York • Rochester, New York

Conditions: Pneumococcal Disease
Interventions: PG4 Multivalent Vaccine, 20 Valent Pneumococcal Conjugate Vaccine (20vPnC); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 4,701 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 37
States / cities: Birmingham, Alabama • Lake Forest, California • Walnut Creek, California + 29 more

Conditions: Streptococcus Pneumoniae Infection, Legionella Pneumophila Serogroup 1 Infection
Interventions: N/A- There is no intervention.; Other
Lead sponsor: Meridian Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Pneumonia, Pneumococcal, Vaccine
Interventions: Pneumococcal Vaccine Education; Behavioral
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years to 64 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Wilkes-Barre, Pennsylvania

Search by objective public record fields.

A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults

Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients

Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease

A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)

Immune Response to Pneumococcal Vaccination in HIV Infected Individuals

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)

Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™

Recombinant Attenuated Salmonella Typhi Vaccine Vectors Producing Streptococcus Pneumoniae PspA

Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age

Pneumococcal Reference Standard

MISP 60528 Pneumococcal Vaccination

Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)

Humoral Determinants of Immunity to Pneumococcal Infection

Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination

A Study to Learn About How a New Pneumococcal Vaccine Works in Children

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.

Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses

Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)

Effect of Prevnar 13 on Ear Infections in Children

A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults

Curian S. Pneumo/Legionella Assay Beta Clinical Trial Protocol

Pneumonia Vaccine Education Intervention Study